CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive Prenatal Testing

LONDON–(BUSINESS WIRE)–CooperGenomics, a CooperSurgical company which includes Reprogenetics,
Recombine, and Genesis Genetics, is pleased to announce the receipt of
ISO 15189 accreditation for both its London and Nottingham-based
laboratories. Issued by the United Kingdom Accreditation Services
(UKAS), this certification validates the quality and accuracy of the
genetic testing services provided by the laboratories.

The accreditation includes all noninvasive prenatal testing (NIPT),
preimplantation genetic diagnosis (PGD), and preimplantation genetic
screening (PGS) services provided in the CooperGenomics London and
Nottingham facilities. CooperGenomics is the first laboratory in the
United Kingdom to receive such accreditation for NIPT and PGS services.

“We are honoured to have received this accreditation from UKAS,” said
Tony Gordon, PhD, Vice President of Business Development at
CooperGenomics in the UK. “As a leader in the field of reproductive
genetic testing, we pride ourselves on the quality of our services, to
which this certification is a testament.”

About CooperSurgical

For more than 25 years, CooperSurgical has been a leader in
manufacturing and marketing a wide range of trusted and innovative
brands that have assisted clinicians in advancing the standard of health
care for women worldwide. Through an aggressive growth and
diversification strategy, CooperSurgical has evolved its portfolio to
include key products and services for women’s health, fertility and
genetic testing. Our global in vitro fertilization (IVF) segment,
ORIGIO, and our groundbreaking offering from the pioneers of genetic
testing, Recombine/Reprogenetics/Genesis Genetics, complement our
dynamic women’s health care offering.

CooperSurgical, Inc. is a wholly owned subsidiary of The Cooper
Companies (NYSE: COO) and is headquartered in Trumbull, CT. Through the
delivery of insightful technologies and products to health care
providers, we envision a world with healthier babies, individuals, and
families. More information can be found at www.coopersurgical.com.

Contacts

CooperGenomics, a CooperSurgical Company
Sarah Yarnall, 203-895-8197
sarah.yarnall@coopergenomics.com